Abstract:Dysregulation of signaling kinase pathways via mutations favors tumor cell survival and response to therapy and it is common in cancer. Here, we reveal a novel post-translational regulation of kinase pathways and nuclear receptor activity via deubiquitination in acute leukemia. Driven by our previous studies showing the critical role for deubiquitination in T-cell acute lymphoblastic leukemia (T-ALL)(Jin et al., 2019; Zhou et al., 2020), we performed an unbiased analysis of deubiquitinase enzyme levels and association with T-ALL prognosis, coupled to a number of biochemical, molecular and in vivo disease modeling studies. Our characterization of gene expression and functional data for the largest deubiquitinases subfamily, ubiquitin specific peptidase (USP), in cancer patients and cell lines, demonstrated that USP11 plays oncogenic role in lymphoid malignancy and showed that it's highly expressed in high risk of T cell leukemia associated with poor prognosis. USP11 ablation inhibits leukemia growth in vitro and in vivo, sparing normal hematopoiesis and thymus development, suggesting that USP11 could be a therapeutic target in leukemia. USP11 forms a complex with USP7 to deubiquitinate oncogenic lymphocyte cell-specific protein-tyrosine kinase (LCK). Deubiquitination of LCK controls its activity, thus altering T cell receptor signaling. Attenuation of LCK or the deubiquitinase activity leads to increased expression of the glucocorticoid receptor transcript culminating in transcriptional activation of apoptotic target genes and sensitizes primary T-ALL patient samples to glucocorticoids. Taken together, our data unveil how dysregulated deubiquitination controls signaling pathways leading to cancer cell survival and drug response and suggest novel therapeutic combinations to target aggressive leukemia.

De-ubiquitination of ELK-1 by USP17 potentiates mitogenic gene expression and cell proliferation

Data from Akt SUMOylation Regulates Cell Proliferation and Tumorigenesis

The Deubiquitinase USP21 Stabilizes MEK2 to Promote Tumor Growth

USP21 Deubiquitylates Nanog to Regulate Protein Stability and Stem Cell Pluripotency

ERK-mediated Cytoplasmic Retention of USP11 Contributes to Breast Cancer Cell Proliferation by Stabilizing Cytoplasmic P21.

USP11 modulates mitotic progression and senescence by regulating the p53-p21 axis through MDM2 deubiquitination

M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability

Deubiquitinating enzymes USP4 and USP17 finetune the trafficking of PDGFRβ and affect PDGF-BB-induced STAT3 signalling

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism

O-GlcNAcylation stimulates the deubiquitination activity of USP16 and regulates cell cycle progression

The deubiquitinase USP38 promotes cell proliferation through stabilizing c-Myc

ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy

Usp51 Promotes Deubiquitination and Stabilization of Zeb1

3075 – ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LEUKEMIA

Deubiquitinase USP18 Promotes the Progression of Pancreatic Cancer Via Enhancing the Notch1-c-Myc Axis.

The Deubiquitinase USP11 Regulates Cell Proliferation and Ferroptotic Cell Death Via Stabilization of NRF2 USP11 Deubiquitinates and Stabilizes NRF2

Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB

Modulation of ErbB receptor signaling and cell cycle regulation by the deubiquitinating enzyme USP8

The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein

Ubiquitin-specific protease 21 promotes tumorigenicity and stemness of colorectal cancer by deubiquitinating and stabilizing ZEB1